Use of a next generation maleimide in combination with THIOMAB™ antibody technology delivers a highly stable, potent and near homogeneous THIOMAB™ antibody-drug conjugate (TDC) (2017)
Attributed to:
Opening the door to novel antibody fragment-based therapeutics and diagnostics via a "dual click" strategy
funded by
EPSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1039/c7ra04606e
Publication URI: http://dx.doi.org/10.1039/c7ra04606e
Type: Journal Article/Review
Parent Publication: RSC Advances
Issue: 40